Equities analysts expect that AzurRx BioPharma, Inc. (NASDAQ:AZRX) will report earnings of ($0.07) per share for the current quarter, according to Zacks. Zero analysts have made estimates for AzurRx BioPharma’s earnings. AzurRx BioPharma posted earnings of ($0.20) per share during the same quarter last year, which would suggest a positive year over year growth rate of 65%. The business is scheduled to report its next earnings results on Friday, June 25th.
On average, analysts expect that AzurRx BioPharma will report full year earnings of ($0.29) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.23). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.32) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow AzurRx BioPharma.
AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings data on Sunday, May 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.07).
AZRX traded up $0.03 during trading on Thursday, reaching $0.82. 527,295 shares of the stock were exchanged, compared to its average volume of 6,011,151. AzurRx BioPharma has a twelve month low of $0.65 and a twelve month high of $2.63. The business’s 50 day moving average price is $0.84.
A number of institutional investors and hedge funds have recently bought and sold shares of AZRX. Royal Bank of Canada acquired a new position in AzurRx BioPharma during the first quarter worth about $27,000. Newman Dignan & Sheerar Inc. acquired a new position in AzurRx BioPharma during the first quarter worth about $32,000. Jane Street Group LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $74,000. Armistice Capital LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $80,000. Finally, Virtu Financial LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $104,000. 4.21% of the stock is owned by institutional investors and hedge funds.
About AzurRx BioPharma
AzurRx BioPharma, Inc, a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.